推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
solid
顏色
white
溶解度
DMSO: ≥10 mg/mL
H2O: insoluble
儲存溫度
−20°C
SMILES 字串
O.O=C(Nc1cccc2C(=O)C=C(Oc12)c3nnn[nH]3)c4ccc(OCCCCc5ccccc5)cc4.O=C(Nc6cccc7C(=O)C=C(Oc67)c8nnn[nH]8)c9ccc(OCCCCc%10ccccc%10)cc9
InChI
1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2
InChI 密鑰
MSXTUBJFNBZPGC-UHFFFAOYSA-N
生化/生理作用
Pranlukast is a subtype specific CysLT1 receptor antagonist.
Pranlukast is a subtype specific CysLT1 receptor antagonist. Leukotrienes are involved in the inflammation response and are divided into two main classes; leukotriene B4 and cysteinyl-substituted leukotrienes.
特點和優勢
This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
訊號詞
Warning
危險分類
Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
Eun-Sol Ha et al.
Drug design, development and therapy, 9, 3257-3266 (2015-07-08)
The present study was carried out to develop an oral formulation of pranlukast hemihydrate with improved dissolution and oral bioavailability using a surface-modified microparticle. Based on solubility measurements, surface-modified pranlukast hemihydrate microparticles were manufactured using the spray-drying method with hydroxypropylmethyl
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门